Monday, February 16, 2026 2/16/2026

Engineering probiotics for tuberculosis therapy

Award Number: R21AI171819
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2022
PERIOD OF PERFORMANCE END DATE: 05/31/2025

Group Awards By:

View Award Description

Engineering probiotics for tuberculosis therapy - PROJECT SUMMARY The engineering of living cells and microbes is driving a new era of medicine. This transformative approach allows for the genetic programming of living cells to intelligently sense and respond healthy and diseased envi- ronments in the body. Bacteria have specifically generated significant recent interest due to their genetic tracta- bility and ability to infiltrate disease sites. A multitude of studies have shown bacterial delivery of therapeutic payloads selectively into tumor cores, demonstrating specificity and efficacy that is otherwise unattainable with molecular-based therapeutics. Given this paradigm in cancer therapy, bacteria present a unique opportunity to be engineered as intelligent delivery vehicles to inaccessible disease sites. We recently discovered that probiotic E. coli Nissle 1917 (EcN) selectively home to granulomas, pathological regions developed at infection sites including tuberculosis. Tuberculosis kills 1.5 million people each year but conventional antibiotics are limited by toxicity, long treatment courses, and drug resistance. Importantly, while difficult for conventional therapeutics to reach, granulomas possess unique necrotic and hypoxic microenviron- ment similar to tumors that supports selective bacterial colonization. The objective of this proposal is to engineer EcN to home to granulomas and locally produce therapeutics to eliminate pathogenic Mycobacterium tuberculosis. We will use synthetic biology approaches to genetically engi- neer EcN as an intelligent drug delivery vehicle. We will utilize hypoxia-sensing growth circuits that further restrict probiotic growth the hypoxic, necrotic granuloma environment. Using a novel in vitro 3D coculture assay, we will screen a library of antimicrobial proteins to identify the most potent antimycobacterial therapeutic candidates. We will test the therapeutic efficacy of engineered E. coli using mycobacterium granuloma mouse models. This fundamentally new approach to granulomatous disease will open up opportunities to utilize engineered bacteria as therapeutic agent for granulomatous infections.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$1,591 )
2026	2023	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	615 W 131ST ST	NEW YORK	NY	10027	NEW YORK	USA	Allergy and Infectious Diseases Research	000	2	2/12/2026	NON-COMPETING CONTINUATION	-$1,591
														Subtotal = -$1,591

Issue Date FY: 2023 ( Subtotal = $233,850 )
2023	2023	TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE	202 LOW LIBRARY 535 W 116 ST MC 4309,	NEW YORK	NY	10027	NEW YORK	USA	Allergy and Infectious Diseases Research	000	2	5/11/2023	NON-COMPETING CONTINUATION	$233,850
														Subtotal = $233,850

Issue Date FY: 2022 ( Subtotal = $289,699 )
2022	2022	TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE	202 LOW LIBRARY 535 W 116 ST MC 4309,	NEW YORK	NY	10027	NEW YORK	USA	Allergy and Infectious Diseases Research	000	1	5/26/2022	NEW	$289,699
														Subtotal = $289,699

Grand Total All Awards = $521,958

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Engineering probiotics for tuberculosis therapy

Award Number: R21AI171819

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2022

PERIOD OF PERFORMANCE END DATE: 05/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer